Syncom Formulations Appoints Rahul Bankda as MD & Rinki Bankda as WTD
Syncom Formulations' AGM on Sept 30, 2026, approved key management changes. Shri Rahul Vijay Bankda appointed Managing Director and Smt. Rinki Ankit Bankda appointed Whole Time Director, both effective Aug 12, 2026. Smt. Ruchi Jindal re-appointed as Woman Independent Director for five years from June 28, 2027.
The changes in Directorate, especially the appointment of a new Managing Director and Whole Time Director, can have a significant impact on the company's strategic direction and operational execution.
The appointment of key management personnel and the re-appointment of an independent director are generally viewed positively as they indicate stability and continuity in leadership.
Syncom Formulations (India) Limited announced significant changes in its directorate following its 38th Annual General Meeting (AGM) held on September 30, 2026. The members approved the appointment of Shri Rahul Vijay Bankda as a Director and designated him as the Managing Director, effective August 12, 2026.
Additionally, Smt. Rinki Ankit Bankda has been appointed as a Director and designated as the Whole Time Director, also effective August 12, 2026. Both appointments were confirmed by the members at the AGM.
Furthermore, Smt. Ruchi Jindal has been re-appointed as a Woman Independent Director for a second term of five consecutive years, commencing from June 28, 2027, and concluding on June 27, 2032. Shri Rahul Vijay Bankda, son of the past Managing Director, brings over 23 years of experience in business operations and financial management. Smt. Rinki Ankit Bankda, spouse of the current Chairman and Whole Time Director, possesses over 13 years of experience in business operations. Smt. Ruchi Jindal, a Chartered Accountant, has over 13 years of experience in finance and accounts.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.